TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Adverum Biotechnologies ( (ADVM) ) is now available.
On November 20, 2025, Adverum Biotechnologies received a termination notice for its lease at 14 TW Alexander Drive, Durham, North Carolina, effective November 19, 2025. The company agreed to pay $0.1 million and release a $7.4 million promissory note as consideration for the early termination. Additionally, Adverum announced the completion of target enrollment for its Phase 3 ARTEMIS trial on November 19, 2025, marking a significant milestone in its clinical development efforts.
The most recent analyst rating on (ADVM) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.
Spark’s Take on ADVM Stock
According to Spark, TipRanks’ AI Analyst, ADVM is a Neutral.
Adverum Biotechnologies’ overall stock score is primarily impacted by its financial performance, which is currently weak due to persistent losses and cash flow challenges. While technical analysis shows positive momentum, the negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score.
To see Spark’s full report on ADVM stock, click here.
More about Adverum Biotechnologies
Adverum Biotechnologies is a company operating in the biotechnology industry, focusing on developing gene therapies. Its primary product in development is Ixo-vec, a lead candidate aimed at treating ocular diseases.
Average Trading Volume: 630,004
Technical Sentiment Signal: Sell
Current Market Cap: $93.83M
See more data about ADVM stock on TipRanks’ Stock Analysis page.